The National Institute for Health and Care Excellence (NICE) suggested in a new report that setting the prices of cancer therapies parallel to their effectiveness could be a boon to the National Health Service (NHS), Medscape reports.
Implementing outcomes-based contracts would reduce the financial burden on the NHS, per the report, and reward companies for innovative therapies with the performance to back them up.
“While the UK is already among the top countries in the world in making new cancer medicines available to patients, it’s vital for patients and their families that we continue to lead the way,” Cancer Research UK Head of Policy Development Emlyn Samuel says. “Outcome-based payment is a promising way to get some drugs to patients quickly where the NHS and the manufacturer are struggling to agree [on] a fixed price.”
To read the full report on Medscape, click here. (Free subscription required)